Surrozen, Inc./DE Accrued Employee Benefits
Surrozen, Inc./DE (SRZN) had Accrued Employee Benefits of $2.88 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Accrued Liabilities
us-gaap:AccruedEmployeeBenefitsCurrentAndNoncurrent · last filed 2026-08-06
- 2026-06-30: Accrued Employee Benefits $2.88M.
- 2026-03-31: Accrued Employee Benefits $2.29M.
- 2025-12-31: Accrued Employee Benefits $3.58M.
- 2025-09-30: Accrued Employee Benefits $2.77M.
| Period end | Accrued Employee Benefits |
|---|---|
| 2026-06-30 | $2.88M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $2.29M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $3.58M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $2.77M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $2.11M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $1.68M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $2.93M 10-K · filed 2026-03-23 |
| 2024-09-30 | $2.44M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $1.88M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $1.49M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $2.51M 10-K · filed 2025-03-31 |
| 2023-09-30 | $2.42M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $2.46M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $1.87M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $3.96M 10-K · filed 2024-04-10 |
| 2022-09-30 | $3.78M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $2.76M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.79M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $2.89M 10-K · filed 2023-03-31 |
| 2021-09-30 | $2.11M 10-Q · filed 2021-11-15 |
| 2020-12-31 | $1.67M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |